Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Presents New Iclaprim Data at IDWeek|
October 3, 2018
|Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress|
September 25, 2018
|Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences|
September 20, 2018